메뉴 건너뛰기




Volumn 9, Issue 10, 2011, Pages 2109-2111

The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; EV 077; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 80053408596     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04446.x     Document Type: Letter
Times cited : (20)

References (9)
  • 1
    • 34249856499 scopus 로고    scopus 로고
    • New antiplatelet strategies in atherothrombosis and their indications
    • Fontana P, Reny JL. New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg 2007; 34: 10-17.
    • (2007) Eur J Vasc Endovasc Surg , vol.34 , pp. 10-17
    • Fontana, P.1    Reny, J.L.2
  • 2
    • 70349204630 scopus 로고    scopus 로고
    • Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases
    • Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 2009; 5: 479-93.
    • (2009) Future Cardiol , vol.5 , pp. 479-493
    • Sakariassen, K.S.1    Alberts, P.2    Fontana, P.3    Mann, J.4    Bounameaux, H.5    Sorensen, A.S.6
  • 3
    • 0034691261 scopus 로고    scopus 로고
    • Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo
    • Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-40.
    • (2000) Circulation , vol.101 , pp. 2833-2840
    • Audoly, L.P.1    Rocca, B.2    Fabre, J.E.3    Koller, B.H.4    Thomas, D.5    Loeb, A.L.6    Coffman, T.M.7    FitzGerald, G.A.8
  • 4
    • 0032582678 scopus 로고    scopus 로고
    • Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
    • Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998; 273: 28766-72.
    • (1998) J Biol Chem , vol.273 , pp. 28766-28772
    • Borsch-Haubold, A.G.1    Pasquet, S.2    Watson, S.P.3
  • 5
    • 0024588409 scopus 로고
    • Measurements of platelet interaction with components of the vessel wall in flowing blood
    • Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 1989; 169: 37-70.
    • (1989) Methods Enzymol , vol.169 , pp. 37-70
    • Sakariassen, K.S.1    Muggli, R.2    Baumgartner, H.R.3
  • 6
    • 0015861774 scopus 로고
    • Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
    • Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
    • (1973) Biochem Pharmacol , vol.22 , pp. 3099-3108
    • Cheng, Y.1    Prusoff, W.H.2
  • 7
    • 0023137593 scopus 로고
    • Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
    • Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6.
    • (1987) Blood , vol.69 , pp. 180-186
    • Reilly, I.A.1    FitzGerald, G.A.2
  • 8
    • 0347985760 scopus 로고    scopus 로고
    • Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation
    • Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 2004; 556: 227-35.
    • (2004) FEBS Lett , vol.556 , pp. 227-235
    • Roger, S.1    Pawlowski, M.2    Habib, A.3    Jandrot-Perrus, M.4    Rosa, J.P.5    Bryckaert, M.6
  • 9
    • 0033925020 scopus 로고    scopus 로고
    • The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis
    • Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 1724-1728
    • Cayatte, A.J.1    Du, Y.2    Oliver-Krasinski, J.3    Lavielle, G.4    Verbeuren, T.J.5    Cohen, R.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.